Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bone-sparing Chemoradiotherapy for Anal Cancer - A Prospective Phase II Trial Danish Anal Cancer Group Study

NCT05385250 is registered in ClinicalTrials.gov with Karen-Lise Garm Spindler as lead sponsor.

NCT NCT05385250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05385250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bone-sparing Chemoradiotherapy for Anal Cancer - A Prospective Phase II Trial Danish Anal Cancer Group Study
Lead sponsor
Karen-Lise Garm Spindler
Phase
Not applicable
Overall status
Active, not recruiting
Start date
August 23, 2021
Completion date
March 1, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, radiotherapy side effect